Compare Natera Inc. Common Stock (NTRA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Novavax Inc — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Novavax Inc trades at $12.41 (market cap $2.08B). The key difference: Natera Inc. Common Stock is far larger — about 27.4× Novavax Inc's market cap, and Novavax Inc is more actively traded (8,501,139 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| NTRA | NVAX | |
|---|---|---|
Market Cap | $57.03B | $2.08B |
Volume | 1,131,157 | 8,501,139 |
Sector | Health | Health |
52-Week High | $425.64 | $12.82 |
52-Week Low | $179.42 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $56.18B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.
The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
